Expanded Access to ABBV-787
NCT06439966 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-02-12
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-787 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
- DRUG
-
ABBV-787
Intravenous (IV) Infusion
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
NCT02365662 ·Status: TERMINATED ·Phase: PHASE1
-
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
NCT03817515 ·Status: APPROVED_FOR_MARKETING
-
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
NCT02391480 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
NCT00820768 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03071757 ·Status: COMPLETED ·Phase: PHASE1
-
Weekly BI 836880 in Patients With Advanced Solid Tumors
NCT02689505 ·Status: COMPLETED ·Phase: PHASE1
-
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
NCT04777994 ·Status: RECRUITING ·Phase: PHASE1
-
Expanded Access for Marizomib
NCT04644107 ·Status: NO_LONGER_AVAILABLE
-
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
NCT04272203 ·Status: TERMINATED ·Phase: PHASE1
-
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
NCT01193595 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
NCT03234712 ·Status: COMPLETED ·Phase: PHASE1
-
Hepatic Arterial Infusion (HAI) of Abraxane
NCT00732836 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2584702 in Participants With Advanced Cancer
NCT01394003 ·Status: TERMINATED ·Phase: PHASE1
-
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
NCT02561234 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03821935 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
NCT07196644 ·Status: RECRUITING ·Phase: PHASE2
-
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
NCT02589717 ·Status: APPROVED_FOR_MARKETING
-
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
NCT07238075 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
NCT03225989 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
NCT07241039 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
NCT00959127 ·Status: COMPLETED ·Phase: PHASE1
-
LY2275796 in Advanced Cancer
NCT00903708 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of ABT-165 in Subjects With Solid Tumors
NCT01946074 ·Status: COMPLETED ·Phase: PHASE1
-
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
NCT01110486 ·Status: COMPLETED ·Phase: PHASE1